Okayama University Medical Research Updates （OU-MRU） Vol.48
February 03, 2018
Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 03 February 2018
Okayama University research: Nanotechnology-based approach to cancer virotherapy
(Okayama, 03 February) Researchers at Okayama University report in Scientific Reports a promising method for delivering viral DNA, able to eliminate cancerous cells, to a tumor. The approach, involving encapsulation of the DNA in liposomes, has the potential to enable intravenous delivery of virus-based antitumor agents.
The principle behind oncolytic virotherapy, an emerging cancer treatment strategy, is to introduce viruses in tumors to infect and kill cancer cells. The targeted delivery of oncolytic viruses to a tumor site is, however, a bottleneck in the development of the therapy — normally, non-specific administering of such viruses leads to their neutralization by the immune system. Inspired by the potential of using nanoparticles for drug-delivery, Professor Toshiyoshi Fujiwara and Associate Professor Hiroshi Tazawa, Assistant Professor Shinji Kuroda from Okayama University have now shown that encapsulating the DNA of a particular type of virus in nano-sized vesicles with a lipid-bilayer shell (so-called liposomes) does not trigger the immune system, while still inhibiting tumor growth.
Liposomes as drug or ‘agent’ carriers have the advantage of being stable in the bloodstream and can therefore be easily transported. The size of the agent-liposome unit is crucial, however: particles that are too large are usually captured by the reticuloendothelial system (a set of cells forming part of the immune system), whereas too-small particles end up in urine. Professor Fujiwara and colleagues realized that the virus they wanted to use (of a type known as adenovirus, with a diameter of 90 to 100 nm) would result in a too-largeagent-liposome cluster. They therefore encapsulated only the plasmid DNA of the virus — DNA in non-chromosomal form, but still able to replicate.
The scientists first confirmed that their clusters (abbreviated ‘Lipo-pTS’) display proper cytotoxic activity. In both in vitro and in vivo settings, exposure of cancer cells to Lipo-pTS indeed led to cancer cell death from the action of the viral DNA. Then, the research team found that Lipo-pTS has a ‘stealth effect’ on the immune system: the presence or absence of antibodies to the adenovirus providing the DNA used did not influence cytotoxic function. (Previous experiments with the full adenovirus showed that such antibodies, usually present in adult humans as it is the virus causing the common cold, suppress cytotoxic activity.) Importantly, this implies that systemic delivery of Lipo-pTS, i.e. by oral intake or intravenous injection, is possible.
Professor Fujiwara and colleagues point out that, although their study has limitations — they did not perform animal experiments with systemic administration, for example — they believe that it “shows the promising potential of liposome-encapsulated oncolytic adenovirus … for cancer therapy” and they are hopeful that it “will serve as a foundation for development of systemically-deliverable oncolytic viral agents”.
The idea behind virotherapy is to deploy viruses as agents for treating diseases. In oncolytic virotherapy, the viruses in question target cancerous cells. By now, various oncolytic viruses have been clinically trialed. In 2004, Professor Toshiyoshi Fujiwara from Okayama University and colleagues demonstrated the virotherapeutic activity of so-called telomerase-specific oncolytic adenovirus. Now, Professor Fujiwara and colleagues have shown that taking the DNA of the adenovirus and encapsulating it in liposome results in a deliverable antitumor agent.
Liposomes are spherical particles (vesicles) with a shell composed of a lipid bilayer — two facing layers, consisting of phospholipids, forming a membrane. Liposomes can act as a container for e.g. proteins, peptides and nucleotides, and are easily transportable via the bloodstream. As such, they are common nanoparticles for drug delivery.
The Okayama University researchers have now demonstrated that liposomes can be used for transporting oncolytic viral DNA to a tumor, without triggering the immune system — an important step towards the development of systemic-delivery oncolytic virotherapy methods.
Katsuyuki Aoyama, Shinji Kuroda, Toshiaki Morihiro, Nobuhiko Kanaya, Tetsushi Kubota, Yoshihiko Kakiuchi, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa & Toshiyoshi Fujiwara. Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system. Scientific Reports, 7 : 14177, 2017.
Reference (OU-MRU) : Professor Fujiwara’s team
Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testing
Vol.7：Anticancer virus solution provides an alternative to surgery
Vol.21：Combined gene transduction and light therapy targets gastric cancer
Vol.23：Viral-based therapy for bone cancer
Vol.33：Attacking tumors from the inside
Professor Toshiyoshi Fujiwara, M.D., Ph.D.
Department of Gastroenterological Surgery, Okayama
University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku,
Okayama 700-8558, Japan
e-mail : toshi_f(a)md.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm (a) adm.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
Okayama Univ. e-Bulletin: //www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (You Tube): https://www.youtube.com/watch?v=iDL1coqPRYIOkayama University Image Movie (You Tube): https://www.youtube.com/watch?v=KU3hOIXS5kk
Okayama University Medical Research Updates （OU-MRU）Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testingVol.2：Ensuring a cool recovery from cardiac arrestVol.3：Organ regeneration research leaps forwardVol.4：Cardiac mechanosensitive integratorVol.5：Cell injections get to the heart of congenital defectsVol.6：Fourth key molecule identified in bone developmentVol.7：Anticancer virus solution provides an alternative to surgeryVol.8：Light-responsive dye stimulates sight in genetically blind patientsVol.9：Diabetes drug helps towards immunity against cancerVol.10：Enzyme-inhibitors treat drug-resistant epilepsyVol.11：Compound-protein combination shows promise for arthritis treatmentVol.12：Molecular features of the circadian clock system in fruit fliesVol.13：Peptide directs artificial tissue growthVol.14：Simplified boron compound may treat brain tumoursVol.15：Metamaterial absorbers for infrared inspection technologiesVol.16：Epigenetics research traces how crickets restore lost limbsVol.17：Cell research shows pathway for suppressing hepatitis B virusVol.18：Therapeutic protein targets liver diseaseVol.19：Study links signalling protein to osteoarthritisVol.20：Lack of enzyme promotes fatty liver disease in thin patientsVol.21：Combined gene transduction and light therapy targets gastric cancerVol.22：Medical supportive device for hemodialysis catheter punctureVol.23：Development of low cost oral inactivated vaccines for dysenteryVol.24：Sticky molecules to tackle obesity and diabetesVol.25：Self-administered aroma foot massage may reduce symptoms of anxietyVol.26：Protein for preventing heart failureVol.27：Keeping cells in shape to fight sepsisVol.28：Viral-based therapy for bone cancerVol.29：Photoreactive compound allows protein synthesis control with lightVol.30：Cancer stem cells’ role in tumor growth revealedVol.31：Prevention of RNA virus replicationVol.32：Enzyme target for slowing bladder cancer invasionVol.33：Attacking tumors from the insideVol.34：Novel mouse model for studying pancreatic cancerVol.35：Potential cause of Lafora disease revealedVol.36：Overloading of protein localization triggers cellular defectsVol.37：Protein dosage compensation mechanism unravelledVol.38：Bioengineered tooth restoration in a large mammalVol.39：Successful test of retinal prosthesis implanted in ratsVol.40：Antibodies prolong seizure latency in epileptic miceVol.41：Inorganic biomaterials for soft-tissue adhesionVol.42：Potential drug for treating chronic pain with few side effectsVol.43：Potential origin of cancer-associated cells revealedVol.44：Protection from plant extractsVol.45：Link between biological-clock disturbance and brain dysfunction uncoveredVol.46：New method for suppressing lung cancer oncogeneVol.47：Candidate genes for eye misalignment identified